Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr.Reddy's Laboratories Ltd    DRREDDY   INE089A01023

End-of-day quote. End-of-day quote  - 09/26
3191 INR   +0.35%
09/20 Dr. Reddy's Laboratories announces the launch of Paricalcitol Inj..
09/19 AMGEN : Dr. Reddy's Expands Strategic Collaboration with Amgen in In..
09/19 DR REDDY LABORA : Announces the Launch of Paricalcitol Injection in ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Dr. Reddy's Laboratories Limited : Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/05/2013 | 10:15am CEST

Hyderabad, India, March 05, 2013

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa® (zoledronic acid) 4 mg/5 mL Injection in the US market on March 4, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (4 mg/5 mL).

Dr. Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.

Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:
www.drreddys.com

Zometa® is a registered trademark of Novartis AG

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at kedaru@drreddys.com/ +91-40-66834297
Saunak Savla at saunaks@drreddys.com/ +91-40-49002135
Milan Kalawadia (USA) at mkalawadia@drreddys.com/ +1 908-203-4931

Media:
S Rajan at rajans@drreddys.com/ +91-40-49002445

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DR.REDDY'S LABORATORIES LT
09/20 DR REDDY LABORATORIES : Launches generic paricalcitol injection in us
09/20 Dr. Reddy's Laboratories announces the launch of Paricalcitol Injection in th..
09/19 AMGEN : Dr. Reddy's Expands Strategic Collaboration with Amgen in India
09/19 DR REDDY LABORATORIES : Announces the Launch of Paricalcitol Injection in the U...
09/19 Uber means business on this road
09/17 DR REDDY LABORATORIES : To market 3 amgen's drugs in india
09/16 DR REDDY LABORATORIES : listed on Dow Jones Sustainability Indices 2016
09/16 DR REDDY LABORATORIES : . Reddy’s Expands Strategic Collaboration with Amg..
09/14 DR REDDY LABORATORIES : listed on Dow Jones Sustainability Indices 2016
09/14 DR REDDY LABORATORIES : Listed on dow jones sustainability indices
More news
Sector news : Pharmaceuticals - NEC
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/16 Dr. Reddy's to distribute three new Amgen products in India
09/02 Dr. Reddy's launches generic version of antidepressant Wellbutrin in U.S.
08/29 Dr. Reddy's launches generic nitroglycerin tablets in U.S.
07/27 DR. REDDY'S : Continues To Stumble. Longer-Term Thesis Intact
07/27 Dr. Reddy's Laboratories' (RDY) Q2 2016 Results - Earnings Call Transcript
Advertisement
Financials ( INR)
Sales 2017 150 626 M
EBIT 2017 19 787 M
Net income 2017 18 016 M
Debt 2017 11 701 M
Yield 2017 0,60%
P/E ratio 2017 29,88
P/E ratio 2018 21,14
EV / Sales 2017 3,68x
EV / Sales 2018 3,18x
Capitalization 543 268 M
More Financials
Chart DR.REDDY'S LABORATORIES LT
Duration : Period :
Dr.Reddy's Laboratories Lt Technical Analysis Chart | DRREDDY | INE089A01023 | 4-Traders
Full-screen chart
Technical analysis trends DR.REDDY'S LABORA...
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 46
Average target price 3 178  INR
Spread / Average Target -0,14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Gunupati Venkateswara Prasad Co-Chairman, Chief Executive Officer & MD
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Abhijit Mukherjee Chief Operating Officer
Kalpana Jaisingh Morparia Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
DR.REDDY'S LABORATORIE..2.48%8 150
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.18%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
MERCK & CO., INC.19.20%174 098
More Results